Navigation Links
New Methods Could Speed Production of Flu Vaccines

Clinical trials using new strategies show promise for better protection against flu

MONDAY, May 18 (HealthDay News) -- Vaccines made up of virus-like particles (VLPs) could provide stronger and longer-lasting protection against flu viruses than conventional vaccines, researchers say.

Even better, VLP vaccines, which can be grown in cell cultures or plants, can be developed and produced twice as quickly as conventional vaccines, according to research presented May 18 at the 109th General Meeting of the American Society for Microbiology, in Philadelphia.

In early clinical trials, VLP vaccines appear to provide complete protection against both the H5N1 avian influenza virus and the 1918 Spanish influenza virus, said Ted Ross, an assistant professor at the University of Pittsburgh's Center for Vaccine Research.

Adopting the new vaccine strategy may allow public health officials to respond more quickly to emerging influenza pandemics, according to a news release from the American Society for Microbiology.

"The sequence for the recent H1N1 'swine flu' virus was online and available to scientists long before physical samples could be delivered," Ross said in the news release. "It would have been possible to produce VLPs in quantity in as little as 12 weeks, while conventional vaccines require physical samples of the virus, and production can take approximately nine months."

Even without an actual sample of the agent, researchers can generate particles for a vaccine if the genes in the virus have been identified, Ross added.

Injectable vaccines that are currently in use to protect from the seasonal flu consist of three influenza strains that are grown in eggs and then inactivated using chemicals that break the virus up into pieces, according to background information provided in the news release. But because the pieces no longer look like the circulating virus, conventionally produced vaccines do not elicit as strong an immune response as VLPs.

"Virus-like particles look just like a live virus, but they are hollow shells without a genome inside, and they cannot reproduce," Ross said. "Because they look like the virus, they evoke a more robust immune response against the real thing."

Inhaled, mist-based flu vaccines can also elicit a strong immune response, but they are associated with an increased risk of side effects, because they are made with live, attenuated virus, the release noted.

Still, there is disagreement over who should be vaccinated and for what flu viruses, Ross said.

"There is a debate in the influenza community about priming the human population for potential pandemic strains such as H5N1 or 1918," Ross said. "Some researchers advocate adding these strains to the annual flu vaccine. They might not match the next pandemic flu strain exactly, but could provide some protection."

Others contend that it's premature and too costly to vaccinate people against a virus that may never emerge, he said.

More information

The CDC has more on flu vaccines.

-- Jennifer Thomas

SOURCE: American Society for Microbiology, news release, May 18, 2009

Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Webcast Alert: Air Methods to Announce First Quarter 2009 Financial Results
2. Long Term Care Alerting Methods Revealed by Industry Leaders
3. Air Methods Preliminary 1st Qtr. Results Exceed Expectations
4. Air Methods Announces Year 2008 Financial Results and Provides First Quarter 2009 Update
5. Air Methods to Report Fourth Quarter and Fiscal Year 2008 Financial Results on Tuesday, March 10, 2009
6. Frost & Sullivan: Novel Diagnostics Methods Driving the European Cancer IVD Market Towards Early Detection and Prevention
7. Early Detection Methods for Pancreatic Cancer Urgently Needed: A Statement From the Pancreatic Cancer Action Network
8. National Patient Advocate Foundation Founder Testifies Before U.S. Senate Health Committee on Methods to Improve Healthcare Quality and Patient Outcomes
9. Air Methods Provides 4th Quarter Update
10. Activator Methods Introduces Web-Based Seminar Program
11. SpectraScience Awarded U.S. Patent 7,469,160 for Its Unique Methods and Apparatus for Evaluating Image Focus
Post Your Comments:
Related Image:
New Methods Could Speed Production of Flu Vaccines 
(Date:11/25/2015)... ... 25, 2015 , ... Lakeview Health, a Jacksonville-based drug and ... sobriety and show through pictures what a positive difference it makes. The social ... the hashtag #FacesOfGratitude on their Facebook, Twitter, and Instagram accounts. Short stories ...
(Date:11/25/2015)... , ... November 25, 2015 , ... The McHenry County ... recent successful appellate decision obtained by Attorneys Francisco J. Botto and Alex C. Wimmer. ... Illinois Workers’ Compensation Comm’n, 2015 IL App (2d) 130884WC. , According to court documents, ...
(Date:11/25/2015)... ... November 25, 2015 , ... Beddit® has launched a new Android ... The new app features a more intuitive SleepScore™ that rates sleep quality on a ... The SleepScore is created by a proprietary algorithm. Beddit analyzes the data to provide ...
(Date:11/25/2015)... ... November 25, 2015 , ... Today, Mothers Against Drunk Driving (MADD) ... below 10,000 for the first time since 2011. In 2014, there were 9,967 fatalities ... released by the National Highway Traffic Safety Administration (NHTSA), 32,675 people were killed in ...
(Date:11/25/2015)... ... 2015 , ... Privately owned Contract Development and Manufacturing Organization ... current state of the art research, development and manufacturing facility outside of Fort ... capacity as well as to support its clients’ growing research and development and ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... , November 25, 2015 Kitov ... ) (TASE: KTOV), a biopharmaceutical company focused on the ... various clinical conditions, today announced the closing of its ... Shares ( ADSs ), each representing 20 ordinary shares ... 3,158,900 ADSs. The ADSs and warrants were issued in ...
(Date:11/25/2015)... , Nov. 25, 2015 Allergan ... pharmaceutical company, and Rugen Therapeutics, a start-up  biotechnology ... for unmet CNS disorders and funded by the ... they have entered into an exclusive collaboration to ... for Autism Spectrum Disorders (ASD) and Obsessive Compulsive ...
(Date:11/25/2015)... Israel , November 25, 2015 ... "New Investors"), pursuant to which BioLight and the New ... IOPtima Ltd. subsidiary ("IOPtima") via a private placement. The ... of its innovative IOPtimate™ system used in the treatment ... approval pathway process for the IOPtimate™ system with the ...
Breaking Medicine Technology: